By Published: Feb. 23, 2022

New study looks to second generation of novel gene therapy as a way to help dogs with joint pain


When dogs develop osteoarthritis, their demeanor changes drastically. Instead of eagerly getting ready for walks, gleefully tossing around toys and excitedly greeting their humans at the door, dogs with this progressive, joint degeneration disease become listless, lethargic and, at times, irritable.

The painful condition makes life difficult for dogs, but itā€™s also heartbreaking for their owners, who have few options for relieving their beloved petsā€™ discomfort. Now, a novel gene therapy developed at the Ā鶹Ćā·Ń°ęĻĀŌŲ is bringing joy back into the lives of pets and their humans.

ā€œItā€™s very striking,ā€ said Linda Watkins, Ā鶹Ćā·Ń°ęĻĀŌŲBoulder Distinguished Professor in the Department of Psychology and Neuroscience. ā€œItā€™s not just helping the dogs, but when you start talking to owners, they lost their family member. They donā€™t play anymore or want to go for walks because it hurts so badly. Theyā€™ve lost their doghood. And this therapy brings that back. All the things you think of with a happy dog, that comes back again, and owners are so thrilled.ā€

Ā鶹Ćā·Ń°ęĻĀŌŲBoulder neuroscientist Linda Watkins and veterinary pain specialist Dr. Rob Landry.

At the top of the page:ĢżShane the therapy dog was one of the first recipients of this gene-therapy injection invented by Ā鶹Ćā·Ń°ęĻĀŌŲBoulder neuroscientist Linda Watkins for chronic pain (Credit: Casey Cass/Ā鶹Ćā·Ń°ęĻĀŌŲBoulder). Above:ĢżĀ鶹Ćā·Ń°ęĻĀŌŲBoulder neuroscientist Linda Watkins and veterinary pain specialist Dr. Rob Landry (Credit: Casey Cass/Ā鶹Ćā·Ń°ęĻĀŌŲBoulder).

Watkins and Broomfield veterinary pain specialist Dr. Rob Landry are recruiting dogs with severe osteoarthritis (and their owners) to help test the second generation of a non-viral gene therapy in the hopes of moving the improved therapeutic toward a federal veterinary clinical trial.

Dogs that are accepted into the double-blind study must be able to visit Dr. Landryā€™s veterinary hospital regularly for several months for evaluations and assessments. Participation in the study is free, but owners must pay for an initial consultation to determine the dogā€™s eligibility or already have an osteoarthritis diagnosis and X-rays.

Dogs in the control group will get a placebo. However, after the initial study period ends, their owners can opt-in to receiving the free therapy as well, Watkins said.

Natureā€™s anti-inflammatory

Osteoarthritis develops when cartilageā€”the flexible connective tissue that helps cushion the jointsā€”begins to break down, either because of injury, disease, repetitive use, age or some combination of factors.

This deterioration causes progressively worsening inflammation, which leads to pain, discomfort and decreased mobility. Prolonged inflammation, in turn, leads to further deterioration.

The condition is common among senior dogs and large breeds, but thereā€™s no known cure. It can be so painful and debilitating that some owners opt to euthanize their dogs to end their suffering, Dr. Landry said.

The gene therapy drives the production on a natural protein called Interleukin 10, or IL-10, which the body produces to dial back its own inflammation response to an injury or infection.

ā€œThis is natureā€™s own potent anti-inflammatory,ā€ said Watkins, who co-founded the biotechnology company to further develop the therapy.

During an initial study at the , Dr. Landry skillfully injected a solution containing circular DNA molecules directly into dogsā€™ osteoarthritic joints, where it instructed cells within the joint to produce more IL-10, thus reducing inflammation.

In that first round, Watkins and Dr. Landry tried the gene therapy on more than 40 Colorado canine companions, from Siberian huskies to golden retrievers to mixed-breed dogs. They got good results, which led to the launch of human clinical trials for osteoarthritis underway in Australia and California.

Taryn Sargent walks her dog Shane.

Taryn Sargent walks her dog Shane (Credit: Casey Cass/Ā鶹Ćā·Ń°ęĻĀŌŲBoulder).

After the treatment, participating pups could more comfortably walk, run, go up and down stairs and stand up. Their owners also reported improved quality of life and less pain.

ā€œThe dogs are happier and far less dependent on medications,ā€ said Dr. Landry, who is also an adjunct professor in the Ā鶹Ćā·Ń°ęĻĀŌŲBoulder Department of Psychology and Neuroscience. ā€œItā€™s amazing research. Itā€™s made impacts on peopleā€™s lives for sure, and petsā€™ lives without a doubt.ā€

Testing the second-generation therapy

Now, theyā€™ve tweaked the therapy and believe the new version will ā€œcome on stronger and last longer,ā€ Watkins said. After years of delay caused by the coronavirus pandemic, theyā€™re ready to begin testing the second generation of the therapy on dogs.

ā€œFor IL-10 to do its thing, to be an anti-inflammatory, it has to bind and signalā€”it has to talk to the other immune cells and tell them to calm down in order to work,ā€ she said. ā€œWeā€™re now encoding not just IL-10 but also giving it this signaling component. Weā€™re making the Il-10 signal much better so it can do its job better.ā€

With the results of this second dog study, Watkins and Dr. Landry hope to gain approval from the veterinary arm of the for testing the second-generation therapy in canine clinical trials.

After that, they hope to see widespread adoption of the therapy in veterinary practices across the country.

ā€œOwners should think of this as trying to help their own dog, but itā€™s also for the greater good of dogsā€”they can be part of something that can move into an FDA clinical trial to make the world a much better place for dogs with osteoarthritis,ā€ Watkins said.

To determine if your dog is eligible for the study, contact Dr. Rob Landry at Veterinary Care Center in Broomfield.

Online:

Phone: 720-502-5823

Email: office@ccapmvetcare.com